|
gptkbp:instanceOf
|
vaccine
|
|
gptkbp:age
|
18 years and above
|
|
gptkbp:approvedBy
|
gptkb:Bahrain
gptkb:Botswana
gptkb:Cambodia
gptkb:Estonia
gptkb:Greece
gptkb:Guyana
gptkb:Hungary
gptkb:India
gptkb:Iran
gptkb:Mauritius
gptkb:Mexico
gptkb:Mongolia
gptkb:Myanmar
gptkb:Nepal
gptkb:Oman
gptkb:Panama
gptkb:Paraguay
gptkb:Philippines
gptkb:Serbia
gptkb:Slovakia
gptkb:Sri_Lanka
gptkb:Switzerland
gptkb:United_Arab_Emirates
gptkb:Venezuela
gptkb:Vietnam
gptkb:Zimbabwe
gptkb:Maldives
|
|
gptkbp:boosterDoseApproved
|
yes
|
|
gptkbp:boosterDoseInterval
|
6 months after second dose
|
|
gptkbp:clinicalTrialPhase
|
2021
|
|
gptkbp:collaboratedWith
|
gptkb:National_Institute_of_Virology
gptkb:Indian_Council_of_Medical_Research
|
|
gptkbp:contains
|
inactivated SARS-CoV-2 virus
|
|
gptkbp:containsAdjuvant
|
Algel-IMDG
|
|
gptkbp:countryOfOrigin
|
gptkb:India
|
|
gptkbp:developedBy
|
gptkb:Bharat_Biotech
|
|
gptkbp:dosesRequired
|
2
|
|
gptkbp:efficacyAgainstSevereCOVID19
|
93.4%
|
|
gptkbp:efficacyAgainstSymptomaticCOVID19
|
77.8%
|
|
gptkbp:emergencyServices
|
gptkb:India
|
|
gptkbp:emergencyUseAuthorizationDate
|
2021-01-03
|
|
gptkbp:firstAdministered
|
2021-01-16
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Covaxin COVID-19 vaccine
|
|
gptkbp:intervalBetweenDoses
|
4 weeks
|
|
gptkbp:manufacturer
|
gptkb:Bharat_Biotech
|
|
gptkbp:marketedAs
|
gptkb:Covaxin
|
|
gptkbp:routeOfAdministration
|
intramuscular injection
|
|
gptkbp:sideEffect
|
fever
nausea
fatigue
headache
joint pain
muscle pain
pain at injection site
allergic reaction (rare)
|
|
gptkbp:storage
|
2-8°C
|
|
gptkbp:target
|
gptkb:COVID-19
|
|
gptkbp:type
|
inactivated virus vaccine
|
|
gptkbp:website
|
https://www.bharatbiotech.com/covaxin.html
|
|
gptkbp:WHOEmergencyUseListing
|
2021-11-03
|
|
gptkbp:bfsParent
|
gptkb:COVID-19_vaccination
|
|
gptkbp:bfsLayer
|
7
|